Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS Wildtype”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Testing effectiveness (Phase 2)UnknownNCT04466254
What this trial is testing

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 75
Testing effectiveness (Phase 2)Looking for participantsNCT07257653
What this trial is testing

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsRASBRAF+2 more
Zhejiang University 70
Large-scale testing (Phase 3)Ended earlyNCT05223673
What this trial is testing

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Institut de Recherches Internationales Servier 7
Testing effectiveness (Phase 2)UnknownNCT04189055
What this trial is testing

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

Who this might be right for
Cancer Colorectal
Hôpital Franco-Britannique-Fondation Cognacq-Jay 72
Testing effectiveness (Phase 2)Study completedNCT02613221
What this trial is testing

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

Who this might be right for
Colorectal Cancer
Takeda 56
Large-scale testing (Phase 3)Looking for participantsNCT06750094
What this trial is testing

Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Who this might be right for
Colorectal Neoplasms
Janssen Research & Development, LLC 700
Testing effectiveness (Phase 2)Ended earlyNCT01508000
What this trial is testing

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Who this might be right for
Colorectal Cancer MetastaticLiver MetastasesKRAS Wild Type Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC 44
Early research (Phase 1)Ended earlyNCT02199223
What this trial is testing

Regorafenib + Panitumumab for Colorectal Cancers

Who this might be right for
KRAS and NRAS Wild-type Colorectal Cancer
University of Utah 2
Testing effectiveness (Phase 2)Study completedNCT02404935
What this trial is testing

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

Who this might be right for
Metastatic Colorectal Cancer
UNICANCER 139
Testing effectiveness (Phase 2)Study completedNCT02399943
What this trial is testing

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerKRAS WildtypeNRAS Wildtype+1 more
University Health Network, Toronto 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945
What this trial is testing

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more
Academic and Community Cancer Research United 22
Testing effectiveness (Phase 2)Ended earlyNCT01925274
What this trial is testing

PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 19
Testing effectiveness (Phase 2)Study completedNCT02063529
What this trial is testing

FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sun Yat-sen University 101
Testing effectiveness (Phase 2)UnknownNCT02296203
What this trial is testing

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT03446157
What this trial is testing

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Who this might be right for
Cancer of the ColonColon CancerColon Neoplasms+2 more
UNC Lineberger Comprehensive Cancer Center 24
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Ended earlyNCT02316496
What this trial is testing

Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study

Who this might be right for
Colorectal Cancer Metastatic
GERCOR - Multidisciplinary Oncology Cooperative Group 2
Not applicableStudy completedNCT04718038
What this trial is testing

Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

Who this might be right for
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Henan Cancer Hospital 60
Load More Results